Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | CCKBR | P32239 | 8/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | GRN | P28799 | 2/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18838283 | 1.00 | SCN9A (0.41) | SCN9ACCKBRP2RX7GRNSORT1 | |
| SCHEMBL18838271 | 1.00 | SCN9A (0.41) | SCN9ACCKBRP2RX7GRNSORT1 | |
| SCHEMBL18838511 | 0.92 | TAS1R3 (0.46) | SCN9ACCKBRCACNA1ICACNA1H | |
| SCHEMBL18838313 | 0.92 | TAS1R3 (0.46) | SCN9ACCKBRCACNA1ICACNA1H | |
| SCHEMBL18838273 | 0.86 | CCKBR (0.42) | CCKBRP2RX7CACNA1HCYP2D6KCNH2 | |
| SCHEMBL18838286 | 0.86 | CCKBR (0.42) | CCKBRP2RX7CACNA1HCYP2D6KCNH2 | |
| SCHEMBL18838396 | 0.81 | KCNH2 (0.48) | CACNA1ICYP2D6KCNH2 | |
| SCHEMBL18860226 | 0.80 | ENPP2 (0.47) | — | |
| SCHEMBL28678612 | 0.80 | ENPP2 (0.47) | — | |
| SCHEMBL18838494 | 0.80 | ENPP2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | SCN9A 115/4885CCKBR 989/4885P2RX7 233/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | SCN9A 115/4885CCKBR 989/4885P2RX7 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.